SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-23-180612
Filing Date
2023-06-30
Accepted
2023-06-30 17:24:26
Documents
2
Group Members
FAIRMOUNT HEALTHCARE CO-INVEST LPFAIRMOUNT HEALTHCARE FUND II LPFAIRMOUNT HEALTHCARE FUND LPPETER HARWINTOMAS KISELAK

Document Format Files

Seq Description Document Type Size
1 SC 13D d530670dsc13d.htm SC 13D 134864
2 EX-99.1 d530670dex991.htm EX-99.1 10801
  Complete submission text file 0001193125-23-180612.txt   147416
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Subject) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-89456 | Film No.: 231062842
SIC: 2834 Pharmaceutical Preparations

Mailing Address 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428
Business Address 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 267-262-5300
Fairmount Funds Management LLC (Filed by) CIK: 0001802528 (see all company filings)

IRS No.: 364841215 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D